Unfinished Business: Demonstrating Value In Pharmacogenomic Testing

Pharmacogenomic testing and personalized medicine are clearly the wave of the future, but establishing their value to society will be key for their successful adoption, economist Kathryn Phillips, PhD, University of California-San Francisco, maintained at an April 4 symposium sponsored by Johns Hopkins University's Genetics and Public Policy Center